Researchers and patients explore why so few Black individuals sign up for studies and highlight projects that aim to develop better strategies.
A 50-year-old woman presented with multiple pruritic lesions on the right inner thigh of 2 years’ duration. Physical examination revealed...
From the Journals
It’s “likely the case” that the pathobiome – with the gut bacteria Ruminococcus blautia gnavus being an important pathobiont – helps to...
This study sought to compare hidradenitis suppurativa–related pain scores by racial groups.
News from the FDA/CDC
It is the second JAK inhibitor approved for treating alopecia areata, following approval of baricitinib (Olumiant) in June 2022 for alopecia...
When formulating therapeutic regimens for patients with PASH syndrome, it is essential for dermatologists to consider the likelihood of...
The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and...
High placebo response rates in lupus clinical trials are making it difficult to show treatment effectiveness.
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
Results of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept,...
The JAK inhibitor ruxolitinib dramatically improved wound healing and rashes in patients with the very rare disorder.